NCT02158858: An ongoing trial by Constellation Pharmaceuticals
This trial is ongoing. It must report results 3 weeks, 3 days from now.
Full data
| Full entry on ClinicalTrials.gov | NCT02158858 |
|---|---|
| Title | A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 16, 2014 |
| Completion date | Jan. 9, 2025 |
| Required reporting date | Jan. 9, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |